Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
Also called Aquipta and made by AbbVie, NICE has recommended atogepant as an option for preventing chronic and episodic migraines in adults who have had at least 4 migraine days per month and where at least 3 previous preventive treatments have failed.
